Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Non-Current Debt (2016 - 2023)

Cartesian Therapeutics (RNAC) has disclosed Non-Current Debt for 8 consecutive years, with $13.8 million as the latest value for Q2 2023.

  • Quarterly Non-Current Debt fell 39.09% to $13.8 million in Q2 2023 from the year-ago period, while the trailing twelve-month figure was $13.8 million through Jun 2023, down 39.09% year-over-year, with the annual reading at $17.8 million for FY2022, 9.59% down from the prior year.
  • Non-Current Debt for Q2 2023 was $13.8 million at Cartesian Therapeutics, down from $16.2 million in the prior quarter.
  • The five-year high for Non-Current Debt was $25.0 million in Q1 2022, with the low at $6.4 million in Q2 2020.
  • Average Non-Current Debt over 4 years is $20.0 million, with a median of $21.3 million recorded in 2021.
  • The sharpest move saw Non-Current Debt soared 255.57% in 2021, then tumbled 39.09% in 2023.
  • Over 4 years, Non-Current Debt stood at $24.8 million in 2020, then decreased by 20.65% to $19.7 million in 2021, then fell by 9.59% to $17.8 million in 2022, then fell by 22.48% to $13.8 million in 2023.
  • According to Business Quant data, Non-Current Debt over the past three periods came in at $13.8 million, $16.2 million, and $17.8 million for Q2 2023, Q1 2023, and Q4 2022 respectively.